Aanjaneya Lifecare buys Apex Drugs

Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but does not warrant or guarantee their accuracy or date.
Our site takes no responsibility for any investment decisions based on recommendations provided on website.
Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to to our website and any financial deal should be done on their own sole responsibility.

Aanjaneya Lifecare has acquired Apex Drugs and Intermediates (ADIL), an integrated APT and pharma intermediates manufacturing company based in Hyderabad.

The acquisition was valued at Rs 2.5 billion with debt of Rs 1.85 billion and equity dilution of Rs 650 million.